ALXN - Alexion Pharmaceuticals, Inc.
108.77 +0.40 (0.37%)
After hours: 5:59PM EST
| Previous Close | 105.89 |
| Open | 106.84 |
| Bid | 106.18 x 1200 |
| Ask | 108.76 x 1000 |
| Day's Range | 106.02 - 108.44 |
| 52 Week Range | 92.56 - 141.86 |
| Volume | 1,483,593 |
| Avg. Volume | 2,223,280 |
| Market Cap | 23.704B |
| Beta (3Y Monthly) | 1.66 |
| PE Ratio (TTM) | 16.62 |
| EPS (TTM) | 6.52 |
| Earnings Date | Feb 3, 2020 - Feb 7, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 149.45 |
- Zacks
What Bargain Hunting? Tap 5 Stocks With Rising P/E
Bet on these top-ranked stocks with rising P/E for outsized gains.
- Zacks
The Zacks Analyst Blog Highlights: AMETEK, Thermo Fisher Scientific, IQVIA, Lowe's Companies and Alexion Pharmaceuticals
The Zacks Analyst Blog Highlights: AMETEK, Thermo Fisher Scientific, IQVIA, Lowe's Companies and Alexion Pharmaceuticals
- Zacks
Alexion (ALXN) Up 10 % YTD on Soliris & Ultomiris Strength
Alexion's (ALXN) stock rises 10% in the year so far as Soliris maintains momentum and Ultomiris gains further traction.
- Zacks
Alexion (ALXN) is an Incredible Growth Stock: 3 Reasons Why
Alexion (ALXN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- Zacks
5 Most-Loved S&P 500 Stocks on Wall Street
Given the bullishness and record-high market, we have screened for five S&P 500 stocks that are most loved by the brokerage firms.
- Business Wire
Alexion to Present at the 2019 Stifel Healthcare Conference
Alexion Pharmaceuticals today announced that management will present at the 2019 Stifel Healthcare Conference in New York, NY on Tuesday, November 19th, 2019 at 8:35 a.m.
- Barrons.com
Buy Big Biotech — But Not Gilead, Analyst Says
SunTrust initiated most of the big names in biotech with a Buy, but it was less sunny on two of the biggest names in the sector: Gilead Sciences and Regeneron Pharmaceuticals.
- American City Business Journals
Drugmaker Amgen cuts a quarter of its Kendall Square research staff
The layoffs come just a few years after the California-based pharmaceutical company kicked off an expansion in New England.
- Zacks
Celgene (CELG) Hits 52-Week High, Can the Run Continue?
Celgene (CELG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- Zacks
Pharma Sector Tops in October: Best ETFs & Stocks
Pharma sector wins in October, making these ETFs and stocks winners.
- Business Wire
Alexion Announces Data Presentations at 61st American Society of Hematology Annual Meeting
Alexion Pharmaceuticals, Inc. (ALXN) today announced that five scientific data presentations from the company’s complement program will be showcased during the annual meeting of the American Society of Hematology (ASH) in Orlando, Fla., from Dec. 7 to 10, 2019. During the Congress, researchers will present new, long-term safety and efficacy findings through 52 weeks of treatment from the Phase 3 trial of ULTOMIRIS® (ravulizumab-cwvz) in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who had previously received eculizumab treatment, as well as data on breakthrough hemolysis in patients treated with ULTOMIRIS during the extension phase (weeks 27-52) of the two Phase 3 studies involving adult patients with PNH, which together comprise the largest PNH clinical program ever conducted.
- Zacks
Biotech ETFs in Focus on Impressive Q3 Earnings Results
Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q3 earnings results recently.
- Zacks
Has Alexion Pharmaceuticals (ALXN) Outpaced Other Medical Stocks This Year?
Is (ALXN) Outperforming Other Medical Stocks This Year?
- Zacks
The Zacks Analyst Blog Highlights: Alexion, Amgen, Gilead and AMAG
The Zacks Analyst Blog Highlights: Alexion, Amgen, Gilead and AMAG
- Zacks
ALXN or CBM: Which Is the Better Value Stock Right Now?
ALXN vs. CBM: Which Stock Is the Better Value Option?
- Zacks
Try Rising P/E Investing With 5 Top-Ranked Stocks
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
- American City Business Journals
Dicerna ropes in Roche on gene-silencing deal worth up to $1.67B
One of the leading Cambridge biotechs hoping to treat diseases by silencing the genetic causes could get as much as $1.67 billion to develop a treatment for hepatitis B.
- Zacks
Biotech Stock Roundup: Q3 Earnings Beat at ALXN & AMGN, Pipeline Updates & More
Key highlights include earnings updates, collaboration deals, and regulatory and pipeline updates.
- Zacks
Healthcare ETFs Win in October: Here's Why
The healthcare sector, which has been the second-worst performer among the 11 major S&P 500 sectors this year, took the center stage this month with some outperformance compared to other sectors.
- Simply Wall St.
Should You Be Worried About Alexion Pharmaceuticals, Inc.'s (NASDAQ:ALXN) 14% Return On Equity?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
- GlobeNewswire
SHAREHOLDER ALERT: WeissLaw LLP Reminds HLND, TNCB, ACHN, RARX Shareholders About Its Ongoing Investigations
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Highlands Bankshares, Inc. (HLND) in connection with the proposed acquisition of the Company by First Community Bankshares, Inc. (FCBC). Under the terms of the proposed acquisition, HLND shareholders will receive 0.273 shares of FCBC for each HLND share that they own.
- Zacks
Here is Why Growth Investors Should Buy Alexion (ALXN) Now
Alexion (ALXN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- Zacks
Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More
Four drug/biotech stocks are scheduled to release third-quarter results on Oct 29. Let's see how these companies are placed before their earnings call.
- TipRanks
3 ‘Perfect 10’ Biotech Stocks to Buy Amid Volatile Market Environment
When it comes to stocks that can shoot up overnight, biotechs are the name of the game. This group’s extreme volatility lies in the fact that a single piece of good news like promising study results can cause share prices to climb to new heights, while the reverse also holds true.As a result, it’s often difficult to determine if names in this industry represent compelling investments. That being said, there are tools available that can help gauge which biotech stocks are poised for substantial long-term growth.Using TipRanks’ Best Stocks to Buy tool, we were able to zero in on 3 biotech stocks that have achieved a “Perfect 10” Smart Score. The metric weighs a variety of factors and combines them into a single numerical score, with 10 being the highest. Not to mention each has earned a ‘Strong Buy’ consensus rating, according to all of the ratings published by analysts in the last three months. Alexion Pharmaceuticals (ALXN)Alexion wants to improve the lives of patients suffering from rare diseases such as atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), hypophosphatasia (HPP) and other conditions. While best known for its Soliris therapy to treat aHUS, a disease that causes abnormal blood clots to form in small blood vessels in the kidneys, the company has recently expanded its pipeline and has several candidates in development.In its most recent quarter, ALXN highlighted its deals with Eidos, Stealth and Achillion as part of its efforts to diversify its offerings. It also expects to add four new clinical stage assets, including two in Phase 3 development. Bearing this in mind, management raised its total revenue guidance to between $4.86 billion to $4.89 billion. If achieved, this would demonstrate an 18% year-over-year gain at the midpoint of the range.With all of these promising developments, it’s no wonder that nine analysts have published bullish calls in just the last ten days. One of the analysts singing ALXN’s praises is Citigroup’s Mohit Bansal. He argues that the biotech is a growth stock trading like a value stock. He adds that the “strong” revenue guidance and recently expanded pipeline may be of interest to incremental investors. As a result, Bansal reiterated his Buy rating. (To watch Bansal’s track record, click here)The rest of the Street appears to echo the analyst’s sentiment. In just the last three months, ALXN has received 16 Buy ratings and 2 Holds, giving it a ‘Strong Buy’ analyst consensus. Its $155 average price target suggests 48% upside potential. (See Alexion stock analysis on TipRanks) Immunomedics (IMMU)Immunomedics uses antibody-based therapies to develop treatments for cancer, autoimmune and other diseases. With the company recently launching studies back in April and May, buzz surrounding this biotech has been building.The company recently announced the launch of its registrational Phase 3 study for patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer. The study of its IMMU-132 drug will feature patients that have experienced failure of at least two but no more than four prior chemotherapy regimens for metastatic disease. IMMU also launched a Phase 2 open label study of its sacituzumab govitecan therapy to treat advanced solid tumors.On top of these trials, the biotech is recruiting for a Phase 2 trial of sacituzumab govitecan for patients with metastatic (Stage IV) urothelial cancer after failure of a platinum-based regimen and/or anti-PD-1/PD-L1 based therapies. While investors will have to wait for the results from the trials, Piper Jaffray analyst Joseph Catanzaro sees significant upside in store for IMMU.“We believe Immunomedics is very well-positioned within triple-negative breast cancer and urothelial bladder cancer,” he commented. Based on all of the above factors, the analyst reiterated his Buy rating and $20 price target. This price target conveys his confidence in IMMU’s ability to surge 23% over the next twelve months. (To watch Catanzaro’s track record, click here)With only Buy ratings assigned in the last three months, the word on the Street is clear: IMMU is a ‘Strong Buy’. Additionally, it boasts 58% upside potential thanks to its $26 average price target. (See Immunomedics stock analysis on TipRanks) Coherus Biosciences (CHRS)By developing biosimilar treatments, Coherus hopes to give patients access to more affordable drugs. A biosimilar drug is a medicine or therapy that is very similar to an already approved biological medicine. While it may seem counterintuitive to develop a drug that resembles something already on the market, they are beneficial in that they provide more treatment options and potentially reduce costs.Following the January 3 launch of its UDENYCA drug to decrease the occurrence of infection in patients receiving anti-cancer drugs, the company has been performing solidly. CHRS saw its UDENYCA net sales reach about $120 million in the first half of 2019. Management stated that this figure was bolstered by strong exit unit market share of 13% at the end of June.All of this led to a 125% increase in net product revenue from the first quarter to the second. With the company developing a therapy similar to Amgen’s Enbrel drug to treat rheumatoid arthritis, some analysts tell investors CHRS is primed for strong long-term growth.Barclays’ Balaji Prasad is one of the analysts maintaining a bullish thesis. While stating that shares experienced some weakness following AMGN’s favorable Enbrel patent ruling against Novartis, he remains very optimistic. He views any share weakness as an opportunity to add a "fundamentally sound company”. This played into his decision to reiterate his Buy rating and $31 price target. (To watch Prasad’s track record, click here)Similarly, other analysts take a bullish approach when it comes to CHRS. It earns a ‘Strong Buy’ Street consensus based on the 6 Buy ratings assigned over the last three months. The biotech stock’s potential twelve-month gain also comes in at 91% according to its $32 average price target. (See Coherus stock analysis on TipRanks)
- TipRanks
3 ‘Strong Buy’ Stocks Top Investors Are Buying
TipRanks has built a reputation on collecting the right information for investors looking to make informed decisions on their stock purchases. The database includes more than 5,500 of Wall Street’s most prolific financial analysts, rated and ranked by their success rate and average return.As the database has grown, TipRanks has added new features and tools to make the data more flexible for users. Over 10,000 financial bloggers, 44,000 corporate insiders, and 99,000 individual investors have made their stock reviews, purchase decisions, and portfolios available to TipRanks’ algorithms.Today, we’ll look at three stocks through the lens of the TipRanks' Individual Investor Sentiment tool. This nifty tool enables you to pinpoint the most popular stocks from the best-performing investors in any sector. We can also see if top investors are ramping up their holdings over the last month/week, as well as the proportion of the portfolio these investors (on average) dedicate to that stock.Taiwan Semiconductor Manufacturing (TSM)The only company from Taiwan among the world’s top 15 semiconductor manufacturers, Taiwan Semi recorded $34.2 billion in total sales for 2018. The only US company to post higher sales numbers was industry giant Intel, but TSM shows a higher market cap, at $260 billion. Taiwan Semi also pleases shareholders with a generous dividend, paying out a yield of 3.19%, or 62% more than the average yield on the S&P 500.TSM shares make up a modest part of TipRanks’ tracked portfolios, but a slightly larger portion of best performing investors’ holdings. These top sock buyers allocate 2.6% of their holdings to TSM, and sentiment on the stock registers as ‘Very Positive.’ Share holdings among the best performing individual investors have increased in both the last week and the last 30 days.The positive investor sentiment on TSM is reflected in the stock’s share price performance. TSM has been rising steadily (despite a minor slip in July) in the markets since mid-June of this year. The stock is 37.5% higher than its June 17 bottom of $36.47.The Street’s analysts are also bullish on TSM. From Goldman Sachs, Bruce Lu puts a Buy on the stock along with a $55 price target. He writes, “Following a re-examination of industry capacity builds and order revisions, we think we are underestimating the positive impacts on TSMC arising from trade uncertainty.” Lu’s price target indicates a possible 9% upside. (To watch Lu's track record, click here)Credit Suisse’s 4-star analyst Randy Abrams puts another Buy rating on TSM. He said, “While the stock may see profit taking on the rally and high capex with some risks on magnitude of 5G ramps, we remain positive into 2020 from higher share, content, and units in mobile and drivers for its HPC business, which could accelerate 2020 sales +14% YoY.”All in all, the chip maker remains a 'Strong Buy' name among Wall Street analysts. In the last three months, TSM has won 5 back-to-back bullish recommendations. With a return potential of close to 8%, the stock's consensus price target stands at $55.00. (See TSM stock analysis on TipRanks)Alexion Pharmaceuticals (ALXN)Top investors are definitely keeping their eyes open on Alexion, a large-cap ($23.9 billion) bio-pharma. While only 1.9% of all portfolios in the TipRanks database hold Alexion, significantly more, 2.6%, of the top investors are buying this stock. And their holdings have increased by nearly a half-percent in the last month. Taken together, this puts a Very Positive investor outlook on ALXN.ALXN has seen its share price slip 29% since April despite steady gains in the quarterly earnings for the last two years. The company is best-known for Soliris, launched in 2007 as a treatment for two diseases, atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria. The drug received approval in 2011, and at that time was considered the world’s most expensive medication, costing more than $400,000 per patient per year of treatment in the US. Soliris sales exceeded $600 million annually by 2015.In 2015, Alexion received FDA approval for a second rare-disorder treatment, Strensiq, and acquired the rights to a third drug, Kanuma, through acquisition of the parent company. Alexion estimates that Kanuma may generate more than $1 billion in annual sales.Sales numbers like that are reflected in ALXN’s earnings and revenues. In its just-released Q3 report, the company showed $1.26 billion in revenue, far above the year-ago quarter’s $1.03 billion. EPS, at $2.49 per share, was 12% higher than the forecast and 23% higher than the previous Q3. Alexion consistently beats the forecasts in its quarterly earnings reports.5-star analyst Christopher Raymond, of Piper Jaffray, believes that ALXN’s combination of relatively low share price and robust earnings offers a chance to pick up a first-class stock at a discount. He writes, “We remain a buyer of ALXN shares following yet another beat/raise quarter with near flawless execution both commercially and developmentally…” Raymond’s $180 price target suggests an eye-opening 68% upside to this stock. (To watch Raymond's track record, click here)The rest of Wall Street echoes Raymond's bullish play, as TipRanks analytics exhibit ALXN as a Strong Buy. Out of 18 analysts polled in the last 3 months, 16 are bullish on the stock while only two remain sidelined. With a return potential of nearly 46%, the stock’s consensus target price stands at $155.38. (See ALXN stock analysis on TipRanks)Archer-Daniels-Midland (ADM)Our third stock with Very Positive investor sentiment is Archer-Daniels-Midland, ADM. This company is leader in the global food production industry. Headquartered in Chicago, ADM operates a global network comprising hundreds of crop procurement facilities and production plants, which it uses in the development and manufacture of food, beverage, animal feed, and nutraceutical products. It’s a massive industry, and in brings ADM over $64 billion in annual revenue.Like the markets generally, ADM saw losses in 2H18, but earnings have shown moderate rebound since Q2 2019. A hard winter in the US and Canada had a damping effect on earnings, which showed a year-over-year decline, but the 60 cents EPS was a gain of 30% from Q1. Quarterly revenues, at $16.3 billion, were down 4.5% year-over-year, but beat the quarterly forecast by 4.2%. So, a decidedly mixed Q2 report did show some positive signs.Investors remain sanguine on ADM. Even after the quarterly report, the top investors have increased their holdings in this stock by 0.4%, and in the last seven days have increased holdings by 0.2%. One factor that may attract investors is the 3.44% dividend yield. With the S&P 500 stocks averaging just a 2% yield, ADM is well ahead of the curve. The $1.40 annualized payment represents a steady income, and the company has been increasing dividend payments to shareholders reliably for the last 43 years. The payout ratio of 51% indicates a commitment to both rewarding shareholders and keeping the dividend sustainable.Stephens’ 4-star analyst Ben Beinvenu sees ADM as a solid stock to anchor a portfolio. He lays out the bottom line on this one in clear terms: “We think ADM offers investors a consistent capital allocation strategy and solid long-term secular demand exposure at an attractive valuation… fundamentals have been under pressure and earnings are well below average. We think that the current stock price offers patient, value-oriented investors a solid entry point to buy a company that will pay a healthy dividend while we wait for the maturation of new businesses … to drive a return to more normalized earnings power.”Beinvenu gives ADM a $50 price target, suggesting a 22% upside from the current share price of $40.73. On average, the Street’s analysts agree with him; this stock has a Strong Buy analyst consensus rating, based on 3 Buys and 1 Hold. The average price target is $48, implying room for an 18% upside. (See ADM stock analysis on TipRanks)
